Tempus ECG-AF vs Study Watch with Irregular Pulse Monitor (Home)
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your primary objective is to proactively identify patients aged 65 or older at an increased risk of developing new-onset atrial fibrillation within the next 12 months, based on a single 12-lead ECG recording. This tool is ideal for clinical settings to stratify risk in asymptomatic or undiagnosed older patients, facilitating earlier clinical evaluation and potential intervention.
View Tempus ECG-AF →Choose Study Watch with Irregular Pulse Monitor (Home) if…
Choose the Verily Study Watch with Irregular Pulse Monitor (Home) if you require continuous, unobtrusive physiological data collection and on-demand single-channel ECG measurements for detecting irregular pulse rhythms suggestive of atrial fibrillation in a clinical research or home-based healthcare setting. This prescription-only wearable is well-suited for long-term monitoring of adult patients (22 years and older) who are diagnosed with, or susceptible to developing, AF, enabling them to monitor and record their heart rhythms.
View Study Watch with Irregular Pulse Monitor (Home) →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | Study Watch with Irregular Pulse Monitor (Home) |
|---|---|---|
| Pricing | Contact vendor | Unknown |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | Unknown |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Yes AI-estimated | Unknown |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Tempus ECG-AFTempus ECG-AF integrates into existing healthcare facility systems and analyzes standard 12-lead ECGs, streamlining workflow for clinicians. This approach minimizes new patient-facing device management and adherence requirements, which can be a barrier with wearables. While Verily Study Watch offers home monitoring, it introduces the need for patient compliance with wearing the device and new data collection/review workflows for providers.
Clinical Value
Tempus ECG-AFTempus ECG-AF is FDA-cleared to identify patients 65 or older at increased risk of developing AF within the next 12 months from a standard 12-lead ECG, enabling proactive intervention. This predictive capability from a routine test offers significant clinical value for earlier identification and follow-up. Verily Study Watch, while also FDA-cleared for irregular pulse monitoring and on-demand ECG, focuses more on detection in a home setting rather than future risk prediction from a single clinical encounter.
Pricing & Value
Tempus ECG-AFTempus ECG-AF has clear CMS reimbursement available with specific CPT codes (0764T and 0765T) and a Medicare rate of $128.90, effective January 1, 2025. This transparency and established reimbursement pathway significantly enhance its financial viability and value proposition for healthcare providers. Verily Study Watch's pricing is not publicly available and is primarily for clinical research and prescription use, making its economic value harder to assess for typical clinical deployment.
Enterprise Readiness
Tempus ECG-AFTempus ECG-AF is a software solution designed for integration into existing healthcare facility systems, including EHR integrations for patient filtering. It is HIPAA compliant and has a BAA. Verily Study Watch, while FDA-cleared and stating HIPAA compliance with a BAA, is a wearable device that introduces additional complexities related to device management, patient adherence, and data synchronization for an enterprise.
Innovation
Tempus ECG-AFTempus ECG-AF demonstrates significant innovation by leveraging AI to extract predictive insights for *future AF risk* from widely available, standard 12-lead ECGs. This capability to predict risk within 12 months from a single, routine test represents a novel application of AI in cardiology. While Verily Study Watch is innovative as a multi-sensor wearable for unobtrusive continuous monitoring, the concept of wearable ECGs for AF detection is becoming more common.
Support & Docs
TieThe provided structured facts and web search results do not offer sufficient comparative detail regarding the quality, availability, or scope of support and documentation for either Tempus ECG-AF or Verily Study Watch. While Verily has a 'Support' section on its website with some regulatory documents and contact information for other products, specific comparative details for the Study Watch are limited. Tempus also lists a support email and phone number for its cardiology team and a document library. Without more specific information, it is not possible to definitively pick a winner.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | Study Watch with Irregular Pulse Monitor (Home) |
|---|---|---|
| Name | Tempus ECG-AF | Study Watch with Irregular Pulse Monitor (Home) |
| Company | Tempus AI, Inc. | Verily Life Sciences LLC |
| Primary Detection/Analysis | AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. | Irregular pulse monitoring for atrial fibrillation (AFib) detection. |
| ECG Type | 12-lead ECG analysis | On-demand single-channel ECG measurement |
| Target Population/Use | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery, supporting earlier identification and follow-up. | Prescription-only wearable device for clinical research and healthcare use. |
| Device Type | Software solution | Wearable device |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and Study Watch with Irregular Pulse Monitor (Home).